[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nk-t-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nk-t-cell-lymphoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,64,85,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642650","phase-3-tr115-vs-investigators-choice-in-relapsedrefractory-peripheral-tnk-cell-lymphoma-100642650",false,"NCT07639879","TR115 VS Investigator's Choice in Relapsed\u002FRefractory Peripheral T\u002FNK Cell Lymphoma","A Randomized, Controlled, Open-label, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of TR115 in Patients With Relapsed and\u002For Refractory Peripheral T\u002FNK-Cell Lymphoma","Inclusion Criteria:\n\n* Histologically confirmed peripheral T-cell lymphoma (PTCL), including PTCL-NOS, AITL, ALCL, or NKTCL\n* Received at least one prior systemic therapy and prior exposure to at least one novel agent (e.g., chidamide, pralatrexate, brentuximab vedotin, etc.) or refractory\u002Fintolerant to such therapies\n* Age ≥18 years\n* ECOG performance status 0-1\n* At least one measurable lesion per Lugano 2014 criteria (lymph node ≥1.5 cm in longest diameter or extranodal lesion ≥1.0 cm)\n* Adequate organ function, defined as: ANC ≥1.5 × 10⁹\u002FL, Platelets ≥100 × 10⁹\u002FL, Hemoglobin ≥100 g\u002FL, Total bilirubin ≤1.5 × ULN, ALT\u002FAST ≤2.5 × ULN (≤5 × ULN if liver involvement), Creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault), LVEF ≥50%, QTcF \\\u003C450 ms (male), \\\u003C470 ms (female)\n* Willingness to provide archival or fresh tumor tissue\n* Life expectancy ≥3 months\n\nExclusion Criteria:\n\n* Prior treatment with EZH2 or EZH1\u002F2 inhibitors resulting in disease progression (intolerance permitted)\n* Known central nervous system involvement of lymphoma\n* Active uncontrolled infection requiring systemic therapy\n* Significant or uncontrolled cardiovascular disease\n* Prior allogeneic stem cell transplantation or autologous stem cell transplantation within 90 days prior to first dose\n* Pregnancy or lactation, or unwillingness to use effective contraception\n* Other malignancies within 5 years, except adequately treated basal cell carcinoma, squamous cell carcinoma, carcinoma in situ, or thyroid carcinoma\n* Patients planned to receive mitoxantrone liposomal therapy with prior cumulative doxorubicin exposure ≥350 mg\u002Fm² (or equivalent anthracycline exposure)","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a randomized, open-label, multicenter Phase III study evaluating the efficacy and safety of TR115, an EZH2 inhibitor, versus investigator's choice (chidamide, golidocitinib, mitoxantrone liposome, or gemcitabine) in patients with relapsed and\u002For refractory peripheral T\u002FNK-cell lymphoma. Approximately 180 patients will be randomized in a 1:1 ratio. The primary endpoint is progression-free survival (PFS) assessed by an Independent Review Committee (IRC). The key secondary endpoint is overall survival (OS). The study is being conducted at approximately 40 to 60 centers across China.",[26,27],"PTCL","NK T-Cell Lymphoma","NOT_YET_RECRUITING","2026-06-06",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":20},"2026-07-30",{"date":36,"type":20},"2030-07-30",{"name":38,"class":39},"Tarapeutics Science Inc.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":4},"100628095","phase-2-phaes--study-of-golidocitinib-pegaspargase-pd-1-antibody-first-line-for-advanced-enktl-100628095","NCT07457177","Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL","A Single-Arm, Open-Label Phase II Clinical Study to Evaluate the Safety and Efficacy of Golidocitinib in Combination With Pegaspargase and Anti-Programmed Death-1 (PD-1) Monoclonal Antibody as First-Line Therapy for Advanced Extranodal Natural Killer\u002FT-Cell Lymphoma (ENKTL)","Inclusion Criteria:\n\n1. Voluntarily provides written informed consent (ICF) and agrees to comply with study procedures.\n2. Histopathologically confirmed ENKTL per the 2022 WHO Classification of Lymphoid Neoplasms, with no prior systemic anti-lymphoma therapy.\n3. At least one measurable or evaluable lesion per 2014 Lugano Classification:\n\n   Measurable lesion: Lymph node ≥1.5 cm (long axis) × ≥1.0 cm (short axis); extranodal lesion ≥1.0 cm (long axis); if the only measurable lesion was previously irradiated, radiological progression after radiotherapy is required.\n\n   Evaluable lesion: FDG-PET uptake higher than liver in lymph nodes or extranodal sites, consistent with lymphoma.\n4. Age ≥18 years at ICF signing.\n5. Estimated life expectancy ≥12 weeks.\n6. ECOG performance status 0-2.\n\n   Adequate organ and bone marrow function (without supportive care within 14 days):\n7. Hematology: Absolute Neutrophil Count (ANC) ≥1.5×10⁹\u002FL (≥0.5×10⁹\u002FL with bone marrow involvement); Platelet (PLT) ≥100×10⁹\u002FL (≥50×10⁹\u002FL with bone marrow involvement); Hemoglobin (HGB) ≥8.0 g\u002FdL.\n\n   Liver function: Total Bilirubin (TBIL) ≤1.5×ULN (≤3.0×ULN for Gilbert syndrome or liver involvement); Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) ≤2.5×ULN (≤5.0×ULN for liver involvement).\n\n   Renal function: Serum Creatinine (Cr) ≤1.5×ULN or Creatinine Clearance Rate (Ccr) ≥50 mL\u002Fmin (Cockcroft-Gault method).\n\n   Coagulation: International Normalized Ratio (INR) ≤1.5×ULN; Prothrombin Time (PT)\u002FActivated Partial Thromboplastin Time (APTT) ≤1.5×ULN (unless on anticoagulants with stable levels).\n\n   Thyroid function: Thyroid Stimulating Hormone (TSH), Free Thyroxine (FT4), Free Triiodothyronine (FT3) within ±10% of normal range (non-autoimmune TSH abnormalities allowed).\n8. Left Ventricular Ejection Fraction (LVEF) ≥50% by MUGA or echocardiogram.\n9. Resolution of acute toxicities from prior therapies to ≤Grade 1 (CTCAE v5.0) or baseline; irreversible Grade 2 toxicities (e.g., neuropathy, alopecia) are allowed if not worsening.\n10. Women of Childbearing Potential (WOCBP) must have negative serum pregnancy test within 7 days of first dose; WOCBP and male partners must use effective contraception from ICF signing to 6 months after last study drug dose.\n\nExclusion Criteria:\n\n1. Aggressive NK-cell leukemia or ENKTL in leukemic phase.\n2. Concurrent hemophagocytic syndrome.\n3. Lymphoma involvement of central nervous system (CNS) or meninges.\n4. History of other malignancies within 5 years (except cured localized tumors: e.g., basal\u002Fsquamous cell skin cancer, in situ prostate\u002Fcervical\u002Fbreast cancer).\n5. Prior therapy:\n\n   Allogeneic hematopoietic stem cell transplantation (HSCT) within 5 years (allowed if \\>5 years with no graft-versus-host disease).\n\n   Autologous HSCT within 3 months. Prior JAK\u002FSTAT3 inhibitors. Concurrent use of strong CYP3A inducers\u002Finhibitors (unable to discontinue 1 week before first dose).\n\n   Concurrent vitamin K antagonists, antiplatelet agents, or anticoagulants (unable to discontinue 1 week before first dose).\n\n   Systemic glucocorticoids or immunosuppressants within 14 days (local\u002Focular\u002Finhaled\u002Fnasal glucocorticoids or short-term ≤7 days for prophylaxis allowed).\n\n   Cytotoxic chemotherapy within 21 days. Systemic anti-tumor therapy (including mAbs, immunotherapy) within 4 weeks. Major surgery within 6 weeks or radiotherapy within 90 days. Toxin\u002Fisotope-antibody conjugates within 10 weeks. Investigational drugs within 30 days.\n\n   Active infections:\n\n   Active\u002Flatent tuberculosis (PPD positive with induration \\>10 mm or radiological evidence).\n\n   HIV infection. Active chronic hepatitis B (HBsAg positive with HBV DNA \\>2500 copies\u002FmL or 500 IU\u002FmL) or hepatitis C (HCV RNA positive). HBV carriers with controlled HBV DNA and cured HCV are allowed; HBsAg-positive patients require monthly HBV DNA monitoring and prophylactic entecavir until 12 months after anti-tumor therapy.\n6. Active viral infections (e.g., herpes zoster) or bacterial infections requiring IV\u002Foral antimicrobials within 30 days (including pneumonia).\n7. Active autoimmune diseases requiring systemic therapy within 2 years (allowed if inactive for 2 years; hormone replacement therapy for hypothyroidism\u002Fdiabetes is allowed).\n8. Uncontrolled cardiac disease: NYHA Class \\>2 heart failure, unstable angina, myocardial infarction within 1 year, clinically significant arrhythmias requiring treatment.\n9. Prior interstitial lung disease (except radiation-induced asymptomatic disease).\n10. Unresolved Grade \\>1 AEs (except alopecia) from prior therapies.\n11. Hypersensitivity to golidocitinib, pegaspargase, anti-PD-1 mAb, or excipients; history of Grade ≥3 hypersensitivity to mAbs or uncontrolled allergic asthma.\n12. Refractory nausea\u002Fvomiting, chronic gastrointestinal disease, dysphagia, or prior bowel resection affecting drug absorption.\n13. Pregnant or lactating women; unwilling to use contraception.\n14. Psychiatric illness or inability to provide informed consent.\n15. Investigator-determined unsuitability for study participation.",{"count":49,"type":20},40,[51],"PHASE2","Extranodal natural killer\u002FT-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens. Preclinical and clinical evidence suggests that PD-L1 is highly expressed in ENKTL, and PD-1 inhibitors show promising activity, while JAK1 inhibitors (e.g., golidocitinib) can reverse PD-1\u002FPD-L1 inhibitor resistance and enhance anti-tumor immunity. This phase II study aims to evaluate the safety, tolerability, and anti-tumor activity of golidocitinib combined with pegaspargase and anti-PD-1 mAb as first-line therapy for advanced treatment-naive ENKTL, providing a novel therapeutic option for this patient population.",[27],"2026-03-03",{"date":56,"type":32},"2026-03-09",{"date":58,"type":20},"2026-02-10",{"date":60,"type":20},"2030-01-30",{"name":62,"class":63},"LIANG WANG","OTHER",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100614215","phase-2-clinical-study-on-maintenance-therapy-with-selinexor-combined-with-azacitidine-after-allogeneic-hematopoietic-stem-cell-transplantation-for-nkt-cell-lymphoma-100614215","NCT07276698","Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK\u002FT-cell Lymphoma","Inclusion Criteria:\n\n* 1\\. Age range: 18-70 years old, gender not restricted; 2. Diagnosed with NK\u002FT-cell lymphoma (NKTCL) according to the 2022 WHO criteria; 3. Received allogeneic hematopoietic stem cell transplantation for NKTCL, with no restrictions on the type of donor; 4. Bone marrow chimerism is complete donor chimerism (T-cell chimerism \\> 95%); 5. ECOG: 0-1 points; 6. Blood routine must meet the following requirements: (1) ANC \\>= 1.0 × 10\\^9\u002FL; (2) PLT \\>= 75 × 10\\^9\u002FL; 7. The patient must be capable of understanding and willing to participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Those who are known to be allergic to azacitidine or selinexor; 2. Those with active acute GVHD of grade 2 or above; 3. Those with moderate or severe chronic GVHD; 4. Any unstable systemic diseases: including but not limited to unstable angina pectoris, cerebrovascular accident or transient ischemic attack (within 3 months before screening), myocardial infarction (within 3 months before screening), congestive heart failure (NYHA classification \\>= grade III), severe arrhythmia requiring drug treatment after pacemaker implantation, liver, kidney or metabolic diseases; patients with pulmonary hypertension. 5. Those with active uncontrolled infections: with hemodynamic instability related to infection, or new symptoms or signs of infection worsening, or new infection lesions found on imaging, persistent fever without symptoms or signs that cannot be ruled out as infection; 6. HIV-infected individuals; 7. Patients with active hepatitis B (HBV) or active hepatitis C (HCV) requiring antiviral treatment; 8. History of autoimmune diseases; 9. Pregnant or lactating women; 10. Those who are currently receiving other investigational drugs.","70 Years",{"count":72,"type":20},39,[51],"Allogeneic hematopoietic stem cell transplantation is an important treatment method for NK-T cell lymphoma, but the recurrence rate after transplantation is relatively high. Therefore, exploring efficient and low-toxicity maintenance treatment strategies after transplantation is a key challenge for improving prognosis. Previous studies have reported that selinexor and azacitidine show good anti-tumor activity in relapsed\u002Frefractory NKTCL. Thus, we conducted a single-center, single-arm, exploratory study on the efficacy and safety of selinexor combined with azacitidine as maintenance therapy after allogeneic hematopoietic stem cell transplantation for NK\u002FT cell lymphoma, to evaluate the efficacy and safety of the combined regimen, with the aim of providing reference for clinical treatment.",[27],"2025-11-29",{"date":78,"type":32},"2025-12-11",{"date":80,"type":20},"2025-12-30",{"date":82,"type":20},"2029-12-30",{"name":84,"class":63},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":99,"locationsCount":4},"100614218","phase-2-preconditioning-with-a-combination-of-thiotepa-cyclophosphamide-and-busulfan-for-allogeneic-hematopoietic-stem-cell-transplantation-in-the-treatment-of-nkt-cell-lymphoma-100614218","NCT07276737","Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK\u002FT-Cell Lymphoma","Inclusion Criteria:\n\n1\\. Age range: 18-70 years old, gender not restricted. 2. Patients diagnosed with NK\u002FT cell lymphoma through histopathology or flow cytometry, 1) with stage III\u002FIV patients receiving first-line or salvage treatment and achieving remission, 2) stage II patients with relapsed\u002Frefractory disease after salvage treatment achieving remission, 3) patients with NK cell lymphoma\u002Fleukemia receiving first-line or salvage treatment and achieving remission, 4) patients with relapsed\u002Frefractory disease. 3. Patients must have a suitable hematopoietic stem cell donor. 1) The related donor must have at least 5\u002F10 HLA-A, -B, -C, -DQB1, and -DRB1 matching. 2) The unrelated donor must have at least 8\u002F10 HLA-A, -B, -C, -DQB1, and -DRB1 matching. 4. HCT-specific comorbidity index score (HCT-CI) \\\u003C= 2. 5. ECOG: 0-2 points. 6. Liver and kidney functions, as well as heart and lung functions, must meet the following requirements: 1) Serum creatinine \\\u003C= 1.5 × ULN; 2) Cardiac function: Ejection fraction \\>= 50%; 3) Basal oxygen saturation \\> 92%; 4) Total bilirubin \\\u003C= 1.5 × ULN; ALT and AST \\\u003C= 2.0 × ULN; 5) Pulmonary function: DLCO (hemoglobin corrected) \\>= 40% and FEV1 \\>= 50%. 7. Patients must be capable of understanding and willing to participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1\\. Patients allergic to stietap, cyclophosphamide or busulfan or its components. 2. Any unstable systemic diseases: including but not limited to unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 3 months before screening), myocardial infarction (within 3 months before screening), congestive heart failure (NYHA classification ≥ III), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases;patients with pulmonary hypertension. 3. Active and uncontrolled infections: hemodynamic instability related to infection, or new symptoms or signs of infection worsening, or new infection lesions found on imaging, persistent fever without exclusion of infection without symptoms or signs; 4. Grade 2 or higher epilepsy, paralysis, aphasia, new cerebral infarction, severe brain trauma, dementia, Parkinson's disease, schizophrenia 5. HIV-infected patients; 6. Patients with active hepatitis B (HBV) or active hepatitis C (HCV) requiring antiviral treatment; 2.patients with a risk of HBV activation, referring to those with positive hepatitis B surface antigen or core antibody but not receiving anti-hepatitis virus treatment; 7. Pregnant or lactating women; 8. Male and female individuals with reproductive capacity who are unwilling to use contraceptive methods during treatment and within 12 months after treatment; 9. Patients whose study investigators assess have other inadvisable inclusion conditions.\n\n\\-",{"count":92,"type":20},37,[51],"Evaluation of the efficacy and safety of Thiotepa combined with Cyclophosphamide and Busulfan as conditioning regimen before allo-HSCT for the treatment of NK\u002FT cell lymphoma",[27],{"date":78,"type":32},{"date":80,"type":20},{"date":82,"type":20},{"name":84,"class":63},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":70,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":40},"100572378","phase-1-rd13-02-cell-injection-in-patients-with-relapsed-or-refractory-cd7-positive-natural-killert-cell-malignancies-100572378","NCT06732492","RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer\u002FT Cell Malignancies","Inclusion Criteria:\n\n1. Age 3-70\n2. Diagnosis of r\u002Fr NK\u002FT lymphoma.\n3. CD7 positive expression\n4. Bone marrow lymphoblasts ≥5% by morphologic evaluation at screening\n5. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL\u002Fmin, Serum alanine aminotransferase(ALT)\u002Faspartate aminotransferase(AST) \\\u003C 3×upper limit of normal, Total bilirubin \\\u003C 1.5×upper limit of normal or ≤1.5mg\u002Fdl\n6. Left ventricular ejection fraction ≥ 50% .\n7. Baseline oxygen saturation ≥ 92% on room air.\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n9. The estimated survival time is more than 3 months.\n10. Subjects or their legal guardians volunteer to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Subjects with concomitant genetic syndromes associated with bone marrow failure states.\n2. Isolated extramedullary lesions\n3. Subjects with some cardiac conditions will be excluded.\n4. With uncontrolled active central nervous system leukemia (CNSL), cerebrospinal fluid grade Central Nervous System3(CNS3).\n5. History of traumatic brain injury, consciousness disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic disease, which might compromise the ability of the subject to compliance with the obligations under the protocol.\n6. History of malignancy other than non-melanoma skin cancer or carcinoma.\n7. Primary immune deficiency.\n8. Presence of uncontrolled infections.\n9. Subjects with some anticancer therapy before CAR-T infusion will be excluded.\n10. Active uncontrolled acute infections.\n11. Known history of infection with human immunodeficiency virus (HIV); active or latent hepatitis B, hepatitis C and syphilis.\n12. Subjects who are receiving systemic steroid therapy prior to screening.","3 Years",{"count":108,"type":20},10,[110],"PHASE1","This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory natural killer\u002FT cell lymphoma, and to evaluate the pharmacokinetics of CD7 CAR-T in patients。",[27,113,114],"CART Therapy","CD7-positive Relapsed\u002FRefractory Lymphoid Hematologic Malignancies","RECRUITING","2024-12-10",{"date":118,"type":32},"2024-12-13",{"date":120,"type":32},"2024-10-31",{"date":122,"type":20},"2027-12-31",{"name":124,"class":63},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"]